Buck E Rogers

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1527795/publications.pdf Version: 2024-02-01



RUCK F ROCERS

#	Article	IF	CITATIONS
1	2-(4-Hydroxyphenyl)benzothiazole dicarboxylate ester TACN chelators for ⁶⁴ Cu PET imaging in Alzheimer's disease. Dalton Transactions, 2022, 51, 1216-1224.	3.3	8
2	A comparison of 64Cu-labeled bi-terminally PEGylated A20FMDV2 peptides targeting integrin ανβ6. Oncotarget, 2022, 13, 360-372.	1.8	3
3	Neutral Ligands as Potential ⁶⁴ Cu Chelators for Positron Emission Tomography Imaging Applications in Alzheimer's Disease. Inorganic Chemistry, 2022, 61, 4778-4787.	4.0	8
4	⁶⁸ Ga-Labeled Benzothiazole Derivatives for Imaging Aβ Plaques in Cerebral Amyloid Angiopathy. ACS Omega, 2022, 7, 20339-20346.	3.5	6
5	Copper-67-Labeled Bombesin Peptide for Targeted Radionuclide Therapy of Prostate Cancer. Pharmaceuticals, 2022, 15, 728.	3.8	17
6	Preclinical Evaluation of an Engineered Single-Chain Fragment Variable-Fragment Crystallizable Targeting Human CD44. Journal of Nuclear Medicine, 2021, 62, 137-143.	5.0	13
7	Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	62
8	Amphiphilic Distyrylbenzene Derivatives as Potential Therapeutic and Imaging Agents for Soluble and Insoluble Amyloid l² Aggregates in Alzheimer's Disease. Journal of the American Chemical Society, 2021, 143, 10462-10476.	13.7	51
9	Amyloid β-Binding Bifunctional Chelators with Favorable Lipophilicity for ⁶⁴ Cu Positron Emission Tomography Imaging in Alzheimer's Disease. Inorganic Chemistry, 2021, 60, 12610-12620.	4.0	15
10	Practical considerations for quantitative clinical SPECT/CT imaging of alpha particle emitting radioisotopes. Theranostics, 2021, 11, 9721-9737.	10.0	12
11	Metal-chelating benzothiazole multifunctional compounds for the modulation and ⁶⁴ Cu PET imaging of Al² aggregation. Chemical Science, 2020, 11, 7789-7799.	7.4	40
12	Design of a multivalent bifunctional chelator for diagnostic ⁶⁴ Cu PET imaging in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 30928-30933.	7.1	25
13	Radiolabeled 6-(2, 3-Dichlorophenyl)-N4-methylpyrimidine-2, 4-diamine (TH287): A Potential Radiotracer for Measuring and Imaging MTH1. International Journal of Molecular Sciences, 2020, 21, 8860.	4.1	3
14	Structure-activity relationship studies and bioactivity evaluation of 1,2,3-triazole containing analogues as a selective sphingosine kinase-2 inhibitors. European Journal of Medicinal Chemistry, 2020, 206, 112713.	5.5	8
15	Glutaminase Inhibitors Induce Thiol-Mediated Oxidative Stress and Radiosensitization in Treatment-Resistant Cervical Cancers. Molecular Cancer Therapeutics, 2020, 19, 2465-2475.	4.1	25
16	Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP. Scientific Reports, 2020, 10, 10196.	3.3	54
17	Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. Cancer Cell, 2020, 37, 289-307.e9.	16.8	252
18	Myocardial B cells are a subset of circulating lymphocytes with delayed transit through the heart. JCI Insight, 2020, 5, .	5.0	57

BUCK E ROGERS

#	Article	IF	CITATIONS
19	Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies. Science Translational Medicine, 2019, 11, .	12.4	148
20	Translation of ceragenin affinity for bacteria to an imaging reagent for infection. RSC Advances, 2019, 9, 14472-14476.	3.6	1
21	PEGylated peptide to TIP1 is a novel targeting agent that binds specifically to various cancers in vivo. Journal of Controlled Release, 2019, 298, 194-201.	9.9	13
22	Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer. Breast Cancer Research and Treatment, 2018, 169, 523-530.	2.5	59
23	Injectable Hydrogels for Localized Chemotherapy and Radiotherapy in Brain Tumors. Journal of Pharmaceutical Sciences, 2018, 107, 922-933.	3.3	35
24	Aerosol-synthesized siliceous nanoparticles: impact of morphology and functionalization on biodistribution. International Journal of Nanomedicine, 2018, Volume 13, 7375-7393.	6.7	5
25	Novel Structural Modification Based on Evans Blue Dye to Improve Pharmacokinetics of a Somastostatin-Receptor-Based Theranostic Agent. Bioconjugate Chemistry, 2018, 29, 2448-2454.	3.6	20
26	Matched-pair, 86Y/90Y-labeled, bivalent RGD/bombesin antagonist, [RGD-Glu-[DO3A]-6-Ahx-RM2], as a potential theranostic agent for prostate cancer. Nuclear Medicine and Biology, 2018, 62-63, 71-77.	0.6	14
27	Evaluation of ⁶⁴ Cu-Based Radiopharmaceuticals that Target Aβ Peptide Aggregates as Diagnostic Tools for Alzheimer's Disease. Journal of the American Chemical Society, 2017, 139, 12550-12558.	13.7	53
28	Copper import in Escherichia coli by the yersiniabactin metallophore system. Nature Chemical Biology, 2017, 13, 1016-1021.	8.0	112
29	Metabolically Stabilized ⁶⁸ Ga-NOTA-Bombesin for PET Imaging of Prostate Cancer and Influence of Protease Inhibitor Phosphoramidon. Molecular Pharmaceutics, 2016, 13, 1347-1357.	4.6	21
30	AKT Inhibitors Promote Cell Death in Cervical Cancer through Disruption of mTOR Signaling and Glucose Uptake. PLoS ONE, 2014, 9, e92948.	2.5	68
31	Novel hexadentate and pentadentate chelators for 64Cu-based targeted PET imaging. Bioorganic and Medicinal Chemistry, 2014, 22, 2553-2562.	3.0	9
32	Development of a Radiolabeled Irreversible Peptide Ligand for PET Imaging of Vascular Endothelial Growth Factor. Journal of Nuclear Medicine, 2014, 55, 1029-1034.	5.0	8
33	Evaluation of copper-64-labeled somatostatin agonists and antagonist in SSTr2-transfected cell lines that are positive and negative for p53: implications for cancer therapy. Nuclear Medicine and Biology, 2012, 39, 187-197.	0.6	20
34	Copper-64 radiolabeling and biological evaluation of bifunctional chelators for radiopharmaceutical development. Nuclear Medicine and Biology, 2012, 39, 1099-1104.	0.6	42
35	Positron-emission tomography (PET) imaging agents for diagnosis of human prostate cancer: agonist vs. antagonist ligands. In Vivo, 2012, 26, 583-92.	1.3	14
36	Nuclear Uptake and Dosimetry of 64Cu-Labeled Chelator Somatostatin Conjugates in an SSTr2-Transfected Human Tumor Cell Line. Journal of Nuclear Medicine, 2007, 48, 1390-1396.	5.0	28

BUCK E ROGERS

#	Article	IF	CITATIONS
37	Characterization of Somatostatin Receptor Subtype 2 Expression in Stably Transfected A-427 Human Cancer Cells. Molecular Imaging, 2007, 6, 7290.2007.00001.	1.4	21
38	Molecular Imaging of Gastrin-Releasing Peptide Receptor-Positive Tumors in Mice Using ⁶⁴ Cu- and ⁸⁶ Y-DOTAâ^'(Pro ¹ ,Tyr ⁴)-Bombesin(1â^'14). Bioconjugate Chemistry, 2007, 18, 724-730.	3.6	65
39	Intraperitoneal Radioimmunotherapy with a Humanized Anti-TAG-72 (CC49) Antibody with a Deleted CH2 Region. Cancer Biotherapy and Radiopharmaceuticals, 2005, 20, 502-513.	1.0	23
40	MicroPET imaging of gene transfer with a somatostatin receptor-based reporter gene and (94m)Tc-Demotate 1. Journal of Nuclear Medicine, 2005, 46, 1889-97.	5.0	38
41	In Vitro and In Vivo Evaluation of a 64Cu-Labeled Polyethylene Glycol-Bombesin Conjugate. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 25-34.	1.0	42
42	MicroPET Imaging of a Gastrin-Releasing Peptide Receptor-Positive Tumor in a Mouse Model of Human Prostate Cancer Using a 64Cu-Labeled Bombesin Analogue. Bioconjugate Chemistry, 2003, 14, 756-763.	3.6	138
43	Targeted radiotherapy with [90Y]-SMT 487 in mice bearing human nonsmall cell lung tumor xenografts induced to express human somatostatin receptor subtype 2 with an adenoviral vector. Cancer, 2002, 94, 1298-1305.	4.1	42
44	Tumor localization of a radiolabeled bombesin analogue in mice bearing human ovarian tumors induced to express the gastrin-releasing peptide receptor by an adenoviral vector. Cancer, 1997, 80, 2419-2424.	4.1	21